The ESMO presentation in October is the next major catalyst. Traders should watch for abstract release and any pre-ESMO data leaks. The stand-alone therapy data is particularly important as it could de-risk the asset from combination dependency and open a larger addressable market. Given the $26M market cap and 90% analyst bullish consensus, positive data could drive significant upside, but the stock has historically sold off on news (0% win rate at T+20). Consider taking profits into the event or using tight stops.
Price Chart
Executive Summary
Evaxion announced it will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress in October 2026. The data from a phase 2 trial extension will show EVX-01's effect as a stand-alone therapy in advanced melanoma patients, building on previously reported two-year results showing a 75% objective response rate and durable responses. The presentation is a key catalyst for the stock, as positive data could support partnership discussions and late-stage development plans for this lead asset.
Key Facts
- Evaxion will present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 (October 23-27, 2026) in Madrid.
- The data comes from a one-year extension of the phase 2 trial where patients received EVX-01 as stand-alone therapy (without anti-PD-1 combination).
- Previously reported two-year data showed a 75% Objective Response Rate (ORR) with 12 of 16 patients responding, including 4 complete responses, and 92% of patients still responding at two years with no relapses.
- EVX-01 induced an immune response in all patients, with 86% of targeted neoantigens generating potent T-cell responses.
- The global market for melanoma treatments is estimated to grow to $7.4 billion by 2029.
Financial Impact
No financial figures provided; the event is a clinical data presentation at a major medical congress, which could materially impact partnership and valuation prospects for the lead asset EVX-01.
Risk Factors
- Historical performance shows EVAX has a 0% win rate at T+20 across prior reports, indicating the stock tends to sell off after news events.
- The phase 2 trial has only 16 patients — small sample size limits statistical significance and replicability.
- The company is pre-revenue and needs additional capital, as noted in forward-looking statement risk factors.
- Data is not yet released; the presentation is three months away, leaving room for negative pre-event drift or disappointing results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004747 |
| Document: f6k_071726.htm | 0001171843-26-004747 |
| Document: 0001171843-26-004747-index-headers.html | 0001171843-26-004747 |
| Document: 0001171843-26-004747-index.html | 0001171843-26-004747 |
| Document: 0001171843-26-004747.txt | 0001171843-26-004747 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access